romidepsin + ketoconazole

**Romidepsin + ketoconazole** is a combination of two small molecules: **romidepsin**, a histone deacetylase inhibitor used primarily in the treatment of cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL)[2][3][4], and **ketoconazole**, a strong inhibitor of CYP3A4 used as an antifungal agent. This combination is not a marketed product but represents concomitant administration of two agents, where ketoconazole acts as a potent CYP3A4 inhibitor and, when co-administered, significantly increases the plasma concentration of romidepsin by decreasing its metabolic clearance[1][3][4]. Romidepsin acts by inhibiting histone deacetylase, altering gene expression, and inducing apoptosis in cancer cells[2][3][4]. The combination is mainly discussed in the context of drug-drug interactions, specifically highlighting the need for caution due to increased risk of toxicity (e.g., hematologic, gastrointestinal, cardiac)[1][3].

Other names

depsipeptideromidepsinaromidepsineromidepsinum